Financial Ratios

THETA PHARMACEUTICALS LTD.

NSE : SYNCOMBSE : 533157ISIN CODE : INE602K01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE4.120 (0 %)
PREV CLOSE ( ) 4.12
OPEN PRICE ( ) 3.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 163615
TODAY'S LOW / HIGH ( )3.95 4.33
52 WK LOW / HIGH ( )3.95 4.33
NSE4.200 (0 %)
PREV CLOSE( ) 4.20
OPEN PRICE ( ) 4.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 4.20 (50)
VOLUME 332739
TODAY'S LOW / HIGH( ) 3.95 4.30
52 WK LOW / HIGH ( )3.95 4.3
Select year
ParticularsMar2024Mar2023Mar2022Mar2021Mar2020
Operational & Financial Ratios
   Earnings Per Share (Rs)-17.11-15.18-7.55-1.23-2.93
   CEPS(Rs)-11.69-9.41-3.60-0.73-2.36
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)-26.19-9.086.10-4.33-3.10
   Tax Rate(%)0.000.000.000.000.00
Margin Ratios
   Core EBITDA Margin(%)-65.24-67.10-126.08-179.12-9.15
   EBIT Margin(%)-89.15-133.02-241.41-266.70-57.24
   Pre Tax Margin(%)-124.77-178.66-241.41-267.98-58.69
   PAT Margin (%)-124.77-178.66-241.41-267.98-58.69
   Cash Profit Margin (%)-85.20-110.82-115.01-159.25-47.22
Performance Ratios
   ROA(%)-30.00-27.71-15.37-27.95-34.83
   ROE(%)0.000.000.000.000.00
   ROCE(%)-29.64-29.47-24.05-54.33-66.73
   Asset Turnover(x)0.240.160.060.100.59
   Sales/Fixed Asset(x)0.160.110.050.080.83
   Working Capital/Sales(x)-0.29-0.30-0.30-0.11-1.48
Efficiency Ratios
   Fixed Capital/Sales(x)6.339.0522.1013.201.21
   Receivable days137.93117.5140.1840.71165.31
   Inventory Days85.19212.46112.50244.9583.24
   Payable days266.53698.21966.30756.32407.16
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)0.000.000.00-3.33-0.31
   Price/Book(x)0.000.000.00-0.56-0.24
   Yield(%)0.000.00
   EV/Net Sales(x)5.267.2314.8616.221.27
   EV/Core EBITDA(x)-10.60-11.09-12.92-10.27-16.23
   EV/EBIT(x)-5.90-5.44-6.16-6.08-2.23
   EV/CE(x)1.921.361.064.401.43
   M Cap / Sales0.000.000.005.310.15
Growth Ratio
   Net Sales Growth(%)61.46-84.90-39.36-90.82-68.86
   Core EBITDA Growth(%)-22.83-25.3655.86-84.58-0.64
   EBIT Growth(%)-8.2164.9045.1157.25-3.88
   PAT Growth(%)-12.7554.0345.3858.11-2.64
   EPS Growth(%)-12.75-418.03-515.4858.10-2.64
Financial Stability Ratios
   Total Debt/Equity(x)-2.43-5.966.19-1.39-1.91
   Current Ratio(x)0.280.420.480.290.26
   Quick Ratio(x)0.240.330.450.270.15
   Interest Cover(x)-2.50-2.91-208.81-39.54
   Total Debt/Mcap(x)2.488.10

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.